Michail_Petrov-96/iStock via Getty Images Stifel had initiated coverage of Profound Medical (NASDAQ:PROF) with a hold rating, commenting that the company faces hurdles in increasing adoption of its prostate ablation technology…
ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on the company’s lead drug candidate LX2006 in the treatment of…
designer491 Acelyrin (NASDAQ:SLRN) said it is conducting a review of its Phase2/3 clinical trial for its drug izokibep in the treatment of psoriatic arthritis due to dose sequencing errors linked…
monsitj JP Morgan said it was bullish on Insmed (NASDAQ:INSM), Denali (NASDAQ:DNLI), Immunocore (NASDAQ:IMCR), Crinetics (NASDAQ:CRNX), Mirum (NASDAQ:MIRM) and BioCryst (NASDAQ:BCRX), rating all six as overweight in a recent note…
ismagilov Kraig Biocraft Laboratories (OTCQB:KBLB) has updated its filing with the SEC for a proposed $10M offering and uplisting to Nasdaq. Kraig said in its latest filing that it was…